These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 1906696

  • 21. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 22. In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.
    Gu JW, Neu HC.
    Antimicrob Agents Chemother; 1990 Feb; 34(2):189-95. PubMed ID: 2327765
    [Abstract] [Full Text] [Related]

  • 23. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
    Barrett MS, Jones RN, Erwin ME, Johnson DM, Briggs BM.
    Diagn Microbiol Infect Dis; 1991 Feb; 14(5):389-401. PubMed ID: 1665774
    [Abstract] [Full Text] [Related]

  • 24. In vitro antibacterial activity of Q-35, a new fluoroquinolone.
    Ito T, Otsuki M, Nishino T.
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1708-14. PubMed ID: 1329626
    [Abstract] [Full Text] [Related]

  • 25. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
    Rolston KV, Nguyen H, Messer M, LeBlanc B, Ho DH, Bodey GP.
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2263-6. PubMed ID: 2127348
    [Abstract] [Full Text] [Related]

  • 26. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
    King A, Bethune L, Phillips I.
    J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
    [Abstract] [Full Text] [Related]

  • 27. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
    Bongaerts GP, Hoogkamp-Korstanje JA.
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
    [Abstract] [Full Text] [Related]

  • 28. In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.
    Beskid G, Fallat V, Lipschitz ER, McGarry DH, Cleeland R, Chan K, Keith DD, Unowsky J.
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1072-7. PubMed ID: 2782857
    [Abstract] [Full Text] [Related]

  • 29. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics.
    Chin NX, Neu HC.
    J Antimicrob Chemother; 1991 Jun; 27(6):781-91. PubMed ID: 1657856
    [Abstract] [Full Text] [Related]

  • 30. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
    Goldstein EJ, Citron DM.
    Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
    [Abstract] [Full Text] [Related]

  • 31. Activity of new quinolones against ciprofloxacin-resistant staphylococci.
    Forstall GJ, Knapp CC, Washington JA.
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1679-81. PubMed ID: 1656873
    [Abstract] [Full Text] [Related]

  • 32. In vitro activity of CP-74,667. A new fluoroquinolone compared with other quinolones.
    Gu JW, Fang W, Chin NX, Neu HC.
    Diagn Microbiol Infect Dis; 1992 Aug; 15(7):613-20. PubMed ID: 1330421
    [Abstract] [Full Text] [Related]

  • 33. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
    Mirelis B, Navarro F, Miró E, Coll R, Xicota MA, Prats G.
    Drugs Exp Clin Res; 1995 Aug; 21(4):129-38. PubMed ID: 8529525
    [Abstract] [Full Text] [Related]

  • 34. Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.
    Murphy SP, Cormican MG, Jones RN.
    Ir J Med Sci; 1995 Aug; 164(4):271-3. PubMed ID: 8522427
    [Abstract] [Full Text] [Related]

  • 35. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
    Rotstein C, Amsterdam D, Beam TR, Mandell LA, Gorzynski EA.
    Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
    [Abstract] [Full Text] [Related]

  • 36. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN, Ballow CH, Schentag JJ, Johnson DM, Deinhart JA.
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [Abstract] [Full Text] [Related]

  • 37. In vitro activity of OPC-17116.
    Neu HC, Fang W, Gu JW, Chin NX.
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1310-5. PubMed ID: 1329620
    [Abstract] [Full Text] [Related]

  • 38. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A, Petersen U, Endermann R.
    Chemotherapy; 1996 Jun; 42(6):410-25. PubMed ID: 8957575
    [Abstract] [Full Text] [Related]

  • 39. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

  • 40. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH, Jones RN, Johnson DM, Deinhart JA, Schentag JJ.
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.